Wuxi Center for Disease Control and Prevention, The Affiliated Wuxi Center for Disease Control and Prevention of Nanjing Medical University, Wuxi, China.
School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2388938. doi: 10.1080/21645515.2024.2388938. Epub 2024 Aug 14.
COVID-19 vaccine hesitancy remains prevalent globally. However, national data on this issue in the general population after the termination of the zero-COVID policy in China are limited. In March 2023, we conducted a nationwide cross-sectional survey among Chinese adults using a self-administered questionnaire. Descriptive statistics and multivariate logistic regressions were employed. Among 4,966 participants, 43.8% reported COVID-19 vaccine hesitancy following the end of the zero-COVID policy in China. Higher rates of vaccine hesitancy were associated with being married (married: OR 1.36, 95%CI 1.17-1.57; other marital status: OR 1.86, 95%CI 1.36-2.55), working in healthcare (OR 1.64, 95%CI 1.38-1.96), having both minors and older adults in the household (OR 1.45, 95%CI 1.20-1.75), having no minors and older adults in the household (OR 1.44, 95%CI 1.17-1.77), having chronic diseases (OR 1.42, 95%CI 1.23-1.64), experiencing adverse events post-vaccination (OR 1.39, 95%CI 1.19-1.61), and uncertainty about previous COVID-19 infection (OR 1.45, 95%CI 1.13-1.86). Conversely, participants who had received the influenza vaccine in the past three years (OR 0.62, 95%CI 0.54-0.72), had previously taken the COVID-19 vaccine (OR 0.44, 95%CI 0.32-0.59), and had higher confidence in vaccines (OR 0.63, 95%CI 0.60-0.67) were less likely to exhibit hesitancy. Our findings indicate a significant level of vaccine hesitancy, underscoring the urgent need for tailored public health strategies to address vaccine hesitancy and improve uptake post-zero-COVID policy in China. A comprehensive understanding of public concerns and related factors is essential for developing effective vaccine communication strategies.
新冠疫苗犹豫在全球范围内仍然普遍存在。然而,在中国结束“动态清零”政策后,关于普通人群对此问题的全国性数据有限。2023 年 3 月,我们使用自填式问卷对中国成年人进行了一项全国性的横断面调查。采用描述性统计和多变量逻辑回归进行分析。在 4966 名参与者中,43.8%的人在中国结束“动态清零”政策后表示对新冠疫苗犹豫不决。更高的疫苗犹豫率与已婚(已婚:OR 1.36,95%CI 1.17-1.57;其他婚姻状况:OR 1.86,95%CI 1.36-2.55)、在医疗保健行业工作(OR 1.64,95%CI 1.38-1.96)、家中有未成年和老年人(OR 1.45,95%CI 1.20-1.75)、家中没有未成年和老年人(OR 1.44,95%CI 1.17-1.77)、患有慢性病(OR 1.42,95%CI 1.23-1.64)、接种疫苗后出现不良反应(OR 1.39,95%CI 1.19-1.61)以及对先前新冠感染的不确定性(OR 1.45,95%CI 1.13-1.86)有关。相反,过去三年中接种过流感疫苗(OR 0.62,95%CI 0.54-0.72)、之前接种过新冠疫苗(OR 0.44,95%CI 0.32-0.59)和对疫苗更有信心(OR 0.63,95%CI 0.60-0.67)的参与者不太可能表现出犹豫。我们的研究结果表明,中国存在显著的疫苗犹豫水平,这突显了迫切需要制定有针对性的公共卫生策略,以解决疫苗犹豫问题,并在中国结束“动态清零”政策后提高疫苗接种率。全面了解公众关注的问题和相关因素对于制定有效的疫苗沟通策略至关重要。